🟢 Veradermics is trading 9% up today after positive Phase 3 results for VDPHL01

Veradermics is trading at $118.10, up 8.53%, after positive Phase 3 Study 304 results for oral hair-loss treatment VDPHL01.

• The October 19 announcement said the trial met all primary and secondary endpoints.
• The 536-participant study showed significant improvements in hair count and patient-reported outcomes versus placebo.
• Trading volume was not provided in the available sources.